rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2007-9-25
|
pubmed:abstractText |
Further optimization of dendritic cell (DC)-based vaccines is required clinically against advanced stage cancer. Given the broad range of expression levels observed in the recently defined tumor antigen EphA2 in a diverse types of cancers, especially in advanced stage or metastatic cancers, the authors evaluated the effectiveness of vaccination using DCs pulsed with EphA2-derived peptides (Eph-DCs) in a murine colon cancer model.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0008-543X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1469-77
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17685394-Animals,
pubmed-meshheading:17685394-Blotting, Western,
pubmed-meshheading:17685394-CD8-Positive T-Lymphocytes,
pubmed-meshheading:17685394-Cancer Vaccines,
pubmed-meshheading:17685394-Carcinoma,
pubmed-meshheading:17685394-Colonic Neoplasms,
pubmed-meshheading:17685394-Dendritic Cells,
pubmed-meshheading:17685394-Disease Models, Animal,
pubmed-meshheading:17685394-Female,
pubmed-meshheading:17685394-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17685394-Interferon-gamma,
pubmed-meshheading:17685394-Mice,
pubmed-meshheading:17685394-Mice, Inbred C57BL,
pubmed-meshheading:17685394-Receptor, EphA2,
pubmed-meshheading:17685394-Time Factors,
pubmed-meshheading:17685394-Up-Regulation
|
pubmed:year |
2007
|
pubmed:articleTitle |
Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|